<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Platelet aggregation is essential for hemostasis but can also cause <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> and <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>A key but poorly understood step in platelet activation is the shift of the principal adhesive receptor, alpha(IIb)beta(3) integrin, from a low- to high-affinity state for its ligands, a process that enables <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> and aggregation </plain></SENT>
<SENT sid="2" pm="."><plain>In response to stimulation of heterotrimeric <z:chebi fb="0" ids="15996">guanosine triphosphate</z:chebi>-binding protein or immunoreceptor tyrosine-based activation motif-coupled receptors, phospholipases cleave membrane <z:chebi fb="1" ids="16247">phospholipids</z:chebi> to generate <z:chebi fb="23" ids="18059">lipid</z:chebi> and soluble second messengers </plain></SENT>
<SENT sid="3" pm="."><plain>An essential role in platelet activation has been established for phospholipase C (PLC) but not for PLD and its product <z:chebi fb="0" ids="16337">phosphatidic acid</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Here, we report that platelets from Pld1(-/-) mice displayed impaired alpha(IIb)beta(3) integrin activation in response to major <z:chebi fb="4" ids="48705">agonists</z:chebi> and defective <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> Ib-dependent aggregate formation under high shear conditions </plain></SENT>
<SENT sid="5" pm="."><plain>These defects resulted in protection from <z:mp ids='MP_0005048'>thrombosis</z:mp> and ischemic <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> without affecting tail <z:mp ids='MP_0001914'>bleeding</z:mp> times </plain></SENT>
<SENT sid="6" pm="."><plain>These results indicate that PLD1 may be a critical regulator of platelet activity in the setting of ischemic cardiovascular and cerebrovascular events </plain></SENT>
</text></document>